---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-034207"
form_type: "8-K"
ticker: "PTCT"
cik: "0001070081"
company_name: "PTC THERAPEUTICS, INC."
filed_at: "2026-03-25T23:59:59+00:00"
generated_at: "2026-05-15T08:57:55.883219+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# PTC Therapeutics appoints biotech banking veteran Jessica Chutter to board

## Summary
- Jessica Chutter appointed to board effective March 24, 2026, as Class I director.
- Chutter spent 40+ years at Morgan Stanley, most recently as Managing Director and Chair of Biotech Investment Banking.
- She was involved in ~$80B in capital raising and ~$85B in strategic transactions at Morgan Stanley.
- Initial director equity grant: 3,475 stock options (36-month monthly vest) and 4,000 RSUs (3-year annual vest).
- Also receives pro-rated annual grant: 2,896 stock options and 3,333 RSUs; eligible for future grants per board policy.

## SEC filing metadata
- accession: 0001104659-26-034207
- form_type: 8-K
- ticker: PTCT
- cik: 0001070081
- company_name: PTC THERAPEUTICS, INC.
- filed_at: 2026-03-25T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070081/000110465926034207/0001104659-26-034207-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070081/000110465926034207/tmb-20260324x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-034207
- JSON: https://secwatch.observer/filing/0001104659-26-034207.json
- Plain text: https://secwatch.observer/filing/0001104659-26-034207.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.